1 | dosing | 6,445 |
2 | fractionation | 894 |
3 | self-weighing | 61 |
4 | teasing | 31 |
5 | 012 | 26 |
6 | up-dosing | 24 |
7 | fractionations | 22 |
8 | dose-fractionation | 18 |
9 | cisca/vb | 14 |
10 | c/l | 10 |
11 | pbbd | 9 |
12 | 3-snip | 8 |
13 | long-cycle | 8 |
14 | lv/5-fu | 8 |
15 | backwashing | 7 |
16 | signal-processing | 6 |
17 | cisplatin/cyclophosphamide | 5 |
18 | dose-doubling | 5 |
19 | itolizumab | 5 |
20 | levonorgestrel-only | 5 |
21 | chemoimmunotherapeutic | 4 |
22 | cord-care | 4 |
23 | glaciations | 4 |
24 | operand | 4 |
25 | patch-use | 4 |
26 | va-guided | 4 |
27 | warfarin-dosing | 4 |
28 | buprenorphine-based | 3 |
29 | chop-ice | 3 |
30 | daclatasvir-containing | 3 |
31 | fluid-free | 3 |
32 | mfolfoxiri | 3 |
33 | regimen/hpufsh-gnrhant | 3 |
34 | sparse-sampling | 3 |
35 | unwrapping | 3 |
36 | 'sparing | 2 |
37 | +dp | 2 |
38 | 11.25- | 2 |
39 | 124-day | 2 |
40 | 17-a4-neurop | 2 |
41 | 5-fu-modulated | 2 |
42 | acquisition/contrast | 2 |
43 | atazanavir-including | 2 |
44 | block-replacement | 2 |
45 | chop-bleo | 2 |
46 | class-sparing | 2 |
47 | cross-docking | 2 |
48 | débridements | 2 |
49 | esa-dosing | 2 |
50 | fennerty | 2 |
51 | flea- | 2 |
52 | gemcitabine-free | 2 |
53 | glic-based | 2 |
54 | hcg-supplemented | 2 |
55 | infusion/flush | 2 |
56 | irinotecan-vincristine | 2 |
57 | machine-smoking | 2 |
58 | medium-equipotency | 2 |
59 | metronidazole/probiotic | 2 |
60 | mifepristone-oxytocin | 2 |
61 | multiaccess | 2 |
62 | optimox1 | 2 |
63 | posological | 2 |
64 | rituximab-chemotherapy | 2 |
65 | single-tnf | 2 |
66 | splint-wearing | 2 |
67 | tablet/lozenge | 2 |
68 | thiacetazone-containing | 2 |
69 | tipranavir-based | 2 |
70 | twelve-fold | 2 |
71 | variable-selection | 2 |
72 | vorinostat-xp | 2 |
73 | +vinorelbine | 1 |
74 | 1-2-day | 1 |
75 | 10-mm/kg | 1 |
76 | 15-repetition | 1 |
77 | 3-agent | 1 |
78 | 4-week-on-2-week-off | 1 |
79 | 7/14-day | 1 |
80 | 95/2000 | 1 |
81 | a6-sized | 1 |
82 | abc/3tc-containing | 1 |
83 | ace-inhibitor-based | 1 |
84 | analytically-based | 1 |
85 | angioregulation | 1 |
86 | anthracenedione/anthracycline | 1 |
87 | arb-containing | 1 |
88 | arb/acei-based | 1 |
89 | bcr-abl-targeted | 1 |
90 | behaviouristic | 1 |
91 | beta1-antagonist | 1 |
92 | bi-chemotherapy | 1 |
93 | bid-treatment | 1 |
94 | bolus-based | 1 |
95 | brushing–rinsing | 1 |
96 | chemotherapy/biologics | 1 |
97 | cilengitide-containing | 1 |
98 | colorprocessing | 1 |
99 | computer-graphic | 1 |
100 | cord-cleansing | 1 |
101 | cosimulation | 1 |
102 | cyp2c8*3*3 | 1 |
103 | ddc/azt | 1 |
104 | desensitization-dosing | 1 |
105 | detoxification/detention | 1 |
106 | device-injection | 1 |
107 | digitalis-diuretic | 1 |
108 | docetaxel-plus-oxalipaltin | 1 |
109 | dosaging | 1 |
110 | dose-inr | 1 |
111 | dose/fractionation | 1 |
112 | dose/immunization | 1 |
113 | doses.ciclesonide | 1 |
114 | doses/administration | 1 |
115 | easier-to-remember | 1 |
116 | epoetin-dosing | 1 |
117 | every-day-life | 1 |
118 | evpome | 1 |
119 | exercise/training | 1 |
120 | fluoroquinolones-sparing | 1 |
121 | g-c-a | 1 |
122 | gatifloxican | 1 |
123 | glycopeptide-based | 1 |
124 | heat-transport | 1 |
125 | hours-35°c | 1 |
126 | hydrocortisone-based | 1 |
127 | hydrokinetics | 1 |
128 | immuno-chemotherapeutic | 1 |
129 | immunodefenses | 1 |
130 | infrequent-dosing | 1 |
131 | infusion-free | 1 |
132 | insulinoterapy | 1 |
133 | interstimuli | 1 |
134 | intervals.aggressive | 1 |
135 | isdn-potentiated | 1 |
136 | ketamine-containing | 1 |
137 | ketamine/medetomidine | 1 |
138 | la-glp-1ra-based | 1 |
139 | loan/insurance | 1 |
140 | lucent | 1 |
141 | maintenace | 1 |
142 | matricing | 1 |
143 | mono-δt3-t0 | 1 |
144 | mri-acquisition | 1 |
145 | multi-dosing | 1 |
146 | multiple-daily-dosing | 1 |
147 | mycophenolate-based | 1 |
148 | non-doxorubicin-containing | 1 |
149 | non-foraging | 1 |
150 | non-mpds | 1 |
151 | nonrifampin | 1 |
152 | nontaxane-containing | 1 |
153 | nontbi | 1 |
154 | past-tense | 1 |
155 | peginterferon-based | 1 |
156 | pfnet | 1 |
157 | pio-based | 1 |
158 | pituitaries | 1 |
159 | posologic | 1 |
160 | present-tense | 1 |
161 | pressure-jump | 1 |
162 | pulsed-therapy | 1 |
163 | radio-enhancing | 1 |
164 | rehabilitation-training | 1 |
165 | repeated-snack | 1 |
166 | retinoid-containing | 1 |
167 | self-care/volunteer | 1 |
168 | short-treatment | 1 |
169 | six-course | 1 |
170 | spiers | 1 |
171 | tdf-ftc-based | 1 |
172 | test-order | 1 |
173 | test/ref | 1 |
174 | therapy-hyperthermia | 1 |
175 | thiotepa-containing | 1 |
176 | time-intensified/dense | 1 |
177 | treatment/intervention | 1 |
178 | treatment/retreatment | 1 |
179 | tzd-based | 1 |
180 | udca-based | 1 |
181 | vmcp/vbap | 1 |
1 | 'sparing | 2 |
2 | +dp | 2 |
3 | +vinorelbine | 1 |
4 | 012 | 26 |
5 | 1-2-day | 1 |
6 | 10-mm/kg | 1 |
7 | 11.25- | 2 |
8 | 124-day | 2 |
9 | 15-repetition | 1 |
10 | 17-a4-neurop | 2 |
11 | 3-agent | 1 |
12 | 3-snip | 8 |
13 | 4-week-on-2-week-off | 1 |
14 | 5-fu-modulated | 2 |
15 | 7/14-day | 1 |
16 | 95/2000 | 1 |
17 | a6-sized | 1 |
18 | abc/3tc-containing | 1 |
19 | ace-inhibitor-based | 1 |
20 | acquisition/contrast | 2 |
21 | analytically-based | 1 |
22 | angioregulation | 1 |
23 | anthracenedione/anthracycline | 1 |
24 | arb-containing | 1 |
25 | arb/acei-based | 1 |
26 | atazanavir-including | 2 |
27 | backwashing | 7 |
28 | bcr-abl-targeted | 1 |
29 | behaviouristic | 1 |
30 | beta1-antagonist | 1 |
31 | bi-chemotherapy | 1 |
32 | bid-treatment | 1 |
33 | block-replacement | 2 |
34 | bolus-based | 1 |
35 | brushing–rinsing | 1 |
36 | buprenorphine-based | 3 |
37 | c/l | 10 |
38 | chemoimmunotherapeutic | 4 |
39 | chemotherapy/biologics | 1 |
40 | chop-bleo | 2 |
41 | chop-ice | 3 |
42 | cilengitide-containing | 1 |
43 | cisca/vb | 14 |
44 | cisplatin/cyclophosphamide | 5 |
45 | class-sparing | 2 |
46 | colorprocessing | 1 |
47 | computer-graphic | 1 |
48 | cord-care | 4 |
49 | cord-cleansing | 1 |
50 | cosimulation | 1 |
51 | cross-docking | 2 |
52 | cyp2c8*3*3 | 1 |
53 | daclatasvir-containing | 3 |
54 | ddc/azt | 1 |
55 | desensitization-dosing | 1 |
56 | detoxification/detention | 1 |
57 | device-injection | 1 |
58 | digitalis-diuretic | 1 |
59 | docetaxel-plus-oxalipaltin | 1 |
60 | dosaging | 1 |
61 | dose-doubling | 5 |
62 | dose-fractionation | 18 |
63 | dose-inr | 1 |
64 | dose/fractionation | 1 |
65 | dose/immunization | 1 |
66 | doses.ciclesonide | 1 |
67 | doses/administration | 1 |
68 | dosing | 6,445 |
69 | débridements | 2 |
70 | easier-to-remember | 1 |
71 | epoetin-dosing | 1 |
72 | esa-dosing | 2 |
73 | every-day-life | 1 |
74 | evpome | 1 |
75 | exercise/training | 1 |
76 | fennerty | 2 |
77 | flea- | 2 |
78 | fluid-free | 3 |
79 | fluoroquinolones-sparing | 1 |
80 | fractionation | 894 |
81 | fractionations | 22 |
82 | g-c-a | 1 |
83 | gatifloxican | 1 |
84 | gemcitabine-free | 2 |
85 | glaciations | 4 |
86 | glic-based | 2 |
87 | glycopeptide-based | 1 |
88 | hcg-supplemented | 2 |
89 | heat-transport | 1 |
90 | hours-35°c | 1 |
91 | hydrocortisone-based | 1 |
92 | hydrokinetics | 1 |
93 | immuno-chemotherapeutic | 1 |
94 | immunodefenses | 1 |
95 | infrequent-dosing | 1 |
96 | infusion-free | 1 |
97 | infusion/flush | 2 |
98 | insulinoterapy | 1 |
99 | interstimuli | 1 |
100 | intervals.aggressive | 1 |
101 | irinotecan-vincristine | 2 |
102 | isdn-potentiated | 1 |
103 | itolizumab | 5 |
104 | ketamine-containing | 1 |
105 | ketamine/medetomidine | 1 |
106 | la-glp-1ra-based | 1 |
107 | levonorgestrel-only | 5 |
108 | loan/insurance | 1 |
109 | long-cycle | 8 |
110 | lucent | 1 |
111 | lv/5-fu | 8 |
112 | machine-smoking | 2 |
113 | maintenace | 1 |
114 | matricing | 1 |
115 | medium-equipotency | 2 |
116 | metronidazole/probiotic | 2 |
117 | mfolfoxiri | 3 |
118 | mifepristone-oxytocin | 2 |
119 | mono-δt3-t0 | 1 |
120 | mri-acquisition | 1 |
121 | multi-dosing | 1 |
122 | multiaccess | 2 |
123 | multiple-daily-dosing | 1 |
124 | mycophenolate-based | 1 |
125 | non-doxorubicin-containing | 1 |
126 | non-foraging | 1 |
127 | non-mpds | 1 |
128 | nonrifampin | 1 |
129 | nontaxane-containing | 1 |
130 | nontbi | 1 |
131 | operand | 4 |
132 | optimox1 | 2 |
133 | past-tense | 1 |
134 | patch-use | 4 |
135 | pbbd | 9 |
136 | peginterferon-based | 1 |
137 | pfnet | 1 |
138 | pio-based | 1 |
139 | pituitaries | 1 |
140 | posologic | 1 |
141 | posological | 2 |
142 | present-tense | 1 |
143 | pressure-jump | 1 |
144 | pulsed-therapy | 1 |
145 | radio-enhancing | 1 |
146 | regimen/hpufsh-gnrhant | 3 |
147 | rehabilitation-training | 1 |
148 | repeated-snack | 1 |
149 | retinoid-containing | 1 |
150 | rituximab-chemotherapy | 2 |
151 | self-care/volunteer | 1 |
152 | self-weighing | 61 |
153 | short-treatment | 1 |
154 | signal-processing | 6 |
155 | single-tnf | 2 |
156 | six-course | 1 |
157 | sparse-sampling | 3 |
158 | spiers | 1 |
159 | splint-wearing | 2 |
160 | tablet/lozenge | 2 |
161 | tdf-ftc-based | 1 |
162 | teasing | 31 |
163 | test-order | 1 |
164 | test/ref | 1 |
165 | therapy-hyperthermia | 1 |
166 | thiacetazone-containing | 2 |
167 | thiotepa-containing | 1 |
168 | time-intensified/dense | 1 |
169 | tipranavir-based | 2 |
170 | treatment/intervention | 1 |
171 | treatment/retreatment | 1 |
172 | twelve-fold | 2 |
173 | tzd-based | 1 |
174 | udca-based | 1 |
175 | unwrapping | 3 |
176 | up-dosing | 24 |
177 | va-guided | 4 |
178 | variable-selection | 2 |
179 | vmcp/vbap | 1 |
180 | vorinostat-xp | 2 |
181 | warfarin-dosing | 4 |
1 | 11.25- | 2 |
2 | flea- | 2 |
3 | 95/2000 | 1 |
4 | mono-δt3-t0 | 1 |
5 | optimox1 | 2 |
6 | 012 | 26 |
7 | cyp2c8*3*3 | 1 |
8 | g-c-a | 1 |
9 | therapy-hyperthermia | 1 |
10 | itolizumab | 5 |
11 | cisca/vb | 14 |
12 | posologic | 1 |
13 | computer-graphic | 1 |
14 | digitalis-diuretic | 1 |
15 | metronidazole/probiotic | 2 |
16 | behaviouristic | 1 |
17 | immuno-chemotherapeutic | 1 |
18 | chemoimmunotherapeutic | 4 |
19 | hours-35°c | 1 |
20 | pbbd | 9 |
21 | va-guided | 4 |
22 | udca-based | 1 |
23 | la-glp-1ra-based | 1 |
24 | glic-based | 2 |
25 | tdf-ftc-based | 1 |
26 | tzd-based | 1 |
27 | glycopeptide-based | 1 |
28 | buprenorphine-based | 3 |
29 | hydrocortisone-based | 1 |
30 | mycophenolate-based | 1 |
31 | arb/acei-based | 1 |
32 | peginterferon-based | 1 |
33 | pio-based | 1 |
34 | tipranavir-based | 2 |
35 | ace-inhibitor-based | 1 |
36 | bolus-based | 1 |
37 | analytically-based | 1 |
38 | isdn-potentiated | 1 |
39 | 5-fu-modulated | 2 |
40 | bcr-abl-targeted | 1 |
41 | hcg-supplemented | 2 |
42 | a6-sized | 1 |
43 | twelve-fold | 2 |
44 | operand | 4 |
45 | maintenace | 1 |
46 | chop-ice | 3 |
47 | loan/insurance | 1 |
48 | cisplatin/cyclophosphamide | 5 |
49 | doses.ciclesonide | 1 |
50 | fluid-free | 3 |
51 | gemcitabine-free | 2 |
52 | infusion-free | 1 |
53 | every-day-life | 1 |
54 | tablet/lozenge | 2 |
55 | long-cycle | 8 |
56 | evpome | 1 |
57 | +vinorelbine | 1 |
58 | ketamine/medetomidine | 1 |
59 | anthracenedione/anthracycline | 1 |
60 | irinotecan-vincristine | 2 |
61 | cord-care | 4 |
62 | time-intensified/dense | 1 |
63 | present-tense | 1 |
64 | past-tense | 1 |
65 | six-course | 1 |
66 | patch-use | 4 |
67 | intervals.aggressive | 1 |
68 | test/ref | 1 |
69 | 4-week-on-2-week-off | 1 |
70 | single-tnf | 2 |
71 | 10-mm/kg | 1 |
72 | matricing | 1 |
73 | radio-enhancing | 1 |
74 | atazanavir-including | 2 |
75 | non-foraging | 1 |
76 | dosaging | 1 |
77 | self-weighing | 61 |
78 | backwashing | 7 |
79 | cross-docking | 2 |
80 | machine-smoking | 2 |
81 | dose-doubling | 5 |
82 | sparse-sampling | 3 |
83 | rehabilitation-training | 1 |
84 | exercise/training | 1 |
85 | thiotepa-containing | 1 |
86 | arb-containing | 1 |
87 | abc/3tc-containing | 1 |
88 | retinoid-containing | 1 |
89 | cilengitide-containing | 1 |
90 | nontaxane-containing | 1 |
91 | ketamine-containing | 1 |
92 | thiacetazone-containing | 2 |
93 | non-doxorubicin-containing | 1 |
94 | daclatasvir-containing | 3 |
95 | unwrapping | 3 |
96 | splint-wearing | 2 |
97 | 'sparing | 2 |
98 | fluoroquinolones-sparing | 1 |
99 | class-sparing | 2 |
100 | teasing | 31 |
101 | cord-cleansing | 1 |
102 | brushing–rinsing | 1 |
103 | dosing | 6,445 |
104 | esa-dosing | 2 |
105 | multi-dosing | 1 |
106 | warfarin-dosing | 4 |
107 | epoetin-dosing | 1 |
108 | desensitization-dosing | 1 |
109 | up-dosing | 24 |
110 | infrequent-dosing | 1 |
111 | multiple-daily-dosing | 1 |
112 | signal-processing | 6 |
113 | colorprocessing | 1 |
114 | infusion/flush | 2 |
115 | nontbi | 1 |
116 | interstimuli | 1 |
117 | mfolfoxiri | 3 |
118 | repeated-snack | 1 |
119 | c/l | 10 |
120 | posological | 2 |
121 | gatifloxican | 1 |
122 | mifepristone-oxytocin | 2 |
123 | nonrifampin | 1 |
124 | docetaxel-plus-oxalipaltin | 1 |
125 | angioregulation | 1 |
126 | cosimulation | 1 |
127 | fractionation | 894 |
128 | dose-fractionation | 18 |
129 | dose/fractionation | 1 |
130 | doses/administration | 1 |
131 | dose/immunization | 1 |
132 | device-injection | 1 |
133 | variable-selection | 2 |
134 | mri-acquisition | 1 |
135 | 15-repetition | 1 |
136 | detoxification/detention | 1 |
137 | treatment/intervention | 1 |
138 | chop-bleo | 2 |
139 | vmcp/vbap | 1 |
140 | +dp | 2 |
141 | 3-snip | 8 |
142 | pressure-jump | 1 |
143 | 17-a4-neurop | 2 |
144 | vorinostat-xp | 2 |
145 | easier-to-remember | 1 |
146 | test-order | 1 |
147 | self-care/volunteer | 1 |
148 | dose-inr | 1 |
149 | chemotherapy/biologics | 1 |
150 | hydrokinetics | 1 |
151 | non-mpds | 1 |
152 | pituitaries | 1 |
153 | immunodefenses | 1 |
154 | glaciations | 4 |
155 | fractionations | 22 |
156 | spiers | 1 |
157 | multiaccess | 2 |
158 | débridements | 2 |
159 | pfnet | 1 |
160 | regimen/hpufsh-gnrhant | 3 |
161 | lucent | 1 |
162 | 3-agent | 1 |
163 | block-replacement | 2 |
164 | bid-treatment | 1 |
165 | short-treatment | 1 |
166 | treatment/retreatment | 1 |
167 | heat-transport | 1 |
168 | acquisition/contrast | 2 |
169 | beta1-antagonist | 1 |
170 | ddc/azt | 1 |
171 | lv/5-fu | 8 |
172 | 1-2-day | 1 |
173 | 7/14-day | 1 |
174 | 124-day | 2 |
175 | medium-equipotency | 2 |
176 | levonorgestrel-only | 5 |
177 | pulsed-therapy | 1 |
178 | rituximab-chemotherapy | 2 |
179 | bi-chemotherapy | 1 |
180 | insulinoterapy | 1 |
181 | fennerty | 2 |